In Phase III clinical trial IMspire150 (NCT02908672), previously untreated, advanced, unresectable BRAFV600E mutant melanoma patients were first treated with targeted therapy of vemurafenib plus cobimetinib for 21 days, followed by vemurafenib monotherapy for seven days, then the triple combination with PD-L1 inhibitor atezolizumab from cycle two onwards. The gene discussed is CD274; the disease is melanoma.